Tuesday , November 21 2017
Home / Resources / Products / Xultophy

Xultophy

 

The first insulin/incretin mimetic combination launched overseas, Xultophy is a prefilled pen containing a fixed-ratio combination of insulin degludec and liraglutide, licensed in Europe for the treatment of type 2 diabetes in combination with oral hypoglycemics. Xultophy is the first product to combine a basal insulin and an incretin mimetic to allow administration of both drugs in a single subcutaneous injection. Regulatory filing in the US is awaiting the additional data required by the FDA for Tresiba.